1	Fu	II Title: Safety, Effectiveness and Immunogenicity of heterologous mRNA-1273
2	Во	ost after Prime with Ad26.COV2.S among Healthcare Workers in South Africa: the
3	sin	gle-arm, open-label, Phase 3 SHERPA Study
4		
5	Sh	ort Title: Safety and Effectiveness of mRNA-1273 Boost after AD26.COV2.S Prime
6		
7	Au	thors: Nigel Garrett ^{1,2} , Tarylee Reddy ³ , Nonhlanhla Yende-Zuma ³ , Azwidhwi Takalani ⁴ ,
8	Ku	bashni Woeber ⁵ , Annie Bodenstein ⁶ , Phumeza Jonas ⁶ , Imke Engelbrecht ⁶ , Waasila
9	Jas	ssat ⁷ , Harry Moultrie ⁷ , Debbie Bradshaw ⁸ , Ishen Seocharan ³ , Jackline Odhiambo ⁴ , Kentse
10	Kh	uto ⁴ , Simone I. Richardson ^{9,10} , Millicent A. Omondi ¹¹ , Rofhiwa Nesamari ¹¹ , Roanne S.
11	Ke	eton ¹¹ , Catherine Riou ^{11,12} , Thandeka Moyo-Gwete ^{9,10} , Craig Innes ¹³ , Zwelethu Zwane ¹³ ,
12	Ka	thy Mngadi ¹³ , William Brumskine ¹³ , Nivashnee Naicker ¹ , Disebo Potloane ¹ , Sharlaa Badal-
13	Fa	esen ¹⁴ , Steve Innes ¹⁵ , Shaun Barnabas ¹⁶ , Johan Lombaard ¹⁷ , Katherine Gill ¹⁵ ,
14	Ma	phoshane Nchabeleng ¹⁸ , Elizma Snyman ¹⁹ , Friedrich Petrick ²⁰ , Elizabeth Spooner ²¹ ,
15	Lo	gashvari Naidoo ²¹ , Dishiki Kalonji ²¹ , Vimla Naicker ²¹ , Nishanta Singh ²¹ , Rebone Maboa ²² ,
16	Pa	mela Mda ²³ , Daniel Malan ²⁴ , Anusha Nana ²⁵ , Mookho Malahleha ²⁶ , Philip Kotze ²⁷ , Jon J.
17	Alla	agappen ²⁸ , Andreas H. Diacon ²⁹ , Gertruida M. Kruger ³⁰ , Faeezah Patel ³¹ , Penny L.
18	Мо	ore ^{1,9,10} , Wendy A. Burgers ^{11,12} , Kate Anteyi ³² , Brett Leav ³² , Linda-Gail Bekker ¹⁵ , Glenda E
19	Gra	ay ³³ , Ameena Goga ^{34,35} and the SHERPA study team
20		
21	Aff	iliations:
22	1.	Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
23	2.	Discipline of Public Health Medicine, School of Nursing and Public Health, University of
24		KwaZulu-Natal, Durban, South Africa
25	3.	Biostatistics Research Unit, South African Medical Research Council (SAMRC), Durban,
26		South Africa
27	4.	Hutchinson Center Research Institute of South Africa, Cape Town, South Africa
28	5.	Grants, Innovation and Product Development Unit, SAMRC, Durban, South Africa

- 29 6. Right to Care, Johannesburg, Gauteng, South Africa
- 30 7. Division of Public Health Surveillance and Response, National Institute for
- 31 Communicable Diseases (NICD) of the National Health Laboratory Services (NHLS),
- 32 Johannesburg, South Africa
- 33 8. Burden of Disease Research Unit, SAMRC, Tygerberg, South Africa
- 34 9. SAMRC Antibody Immunity Research Unit, School of Pathology, University of the
- 35 Witwatersrand, Johannesburg, South Africa.
- 10. Centre for HIV and STIs, NICD of the NHLS, Johannesburg, South Africa.
- 11. Institute of Infectious Disease and Molecular Medicine, Division of Medical Virology,
- 38 Department of Pathology, University of Cape Town, Cape Town, South Africa
- 39 12. Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town,
- 40 Cape Town, South Africa
- 41 13. Aurum Institute, Johannesburg, South Africa
- 42 14. Clinical HIV Research Unit, Johannesburg, South Africa
- 43 15. Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa
- 44 16. Family Centre for Research with Ubuntu, Tygerberg, South Africa
- 45 17. Josha Research, Bloemfontein, South Africa
- 46 18. Medunsa Clinical Research Unit, Sefako Makgatho Health Sciences University, Pretoria,
- 47 South Africa
- 48 19. TASK Eden, George, South Africa
- 49 20. Mzansi Ethical Research Centre, Middelburg, South Africa
- 50 21. SAMRC Clinical Research Site, Durban South Africa
- 51 22. Ndlovu Research Centre, Elandsdoorn, South Africa
- 52 23. Nelson Mandela Academic Research Unit CRS, Mthatha, South Africa
- 53 24. PHOENIX Pharma, Port Elizabeth, South Africa
- 54 25. Perinatal HIV Research Unit, Johannesburg, South Africa
- 55 26. Synergy Biomed Research Institute, East London, South Africa
- 56 27. Qhakaza Mbokodo Research Clinic, Ladysmith, South Africa

- 57 28. Setshaba Research Centre, Soshanguve, South Africa
- 58 29. TASK Central, Cape Town, South Africa
- 59 30. Ubuntu Clinical Research, Gauteng, South Africa
- 60 31. Wits RHI Research Institute, University of Witwatersrand, Johannesburg, South Africa
- 61 32. Moderna Inc., Cambridge, MA, USA
- 62 33. Office of the President and CEO, SAMRC, Cape Town, South Africa
- 63 34. Department of Paediatrics and Child Health, University of Pretoria, Pretoria, South Africa
- 64 35. HIV and other Infectious Diseases Research Unit, SAMRC, Durban, South Africa
- 65
- 66 **Corresponding Author:** Prof Nigel Garrett; 2nd Floor, Doris Duke Medical Research
- 67 Institute (Private Bag X7), 719 Umbilo Road, Congela, Durban 4013, South Africa;
- 68 Email: nigel.garrett@caprisa.org; Phone: +27 31 655 0617
- 69
- 70 Keywords: SARS-CoV-2, COVID-19, Ad26.COV2.S, mRNA-1273, vaccine, booster
- 71

72 Word counts:

- 73 Abstract: 300/300
- 74 Text: 3866
- 75 Tables/Figures: 3 Tables and 3 Figures
- 76

78 Abstract

79 Given limited data on safety and effectiveness of heterologous COVID-19 vaccine boosting 80 in lower income, high-HIV prevalence settings, we evaluated a mRNA-1273 boost after 81 Ad26.COV2.S priming in South Africa. SHERPA was a single-arm, open-label, phase 3 82 study nested in the Sisonke implementation trial of 500000 healthcare workers (HCWs). 83 Sisonke participants were offered mRNA-1273 boosters between May and November 2022, 84 a period of circulating Omicron sub-lineages. Adverse events (AE) were self-reported, and 85 co-primary endpoints (SARS-CoV-2 infections and COVID-19 hospitalizations or deaths) 86 were collected through national databases. We used Cox regression models with booster 87 status as time-varying covariate to determine the relative vaccine effectiveness (rVE) of the 88 mRNA-1273 booster among SHERPA versus unboosted Sisonke participants. Of 11248 89 SHERPA participants in the rVE analysis cohort (79.3% female, median age 41), 45.4% had 90 received one and 54.6% two Ad26.COV2.S doses. Self-reported comorbidities included HIV 91 (18.7%), hypertension (12.9%) and diabetes (4.6%). In multivariable analysis including 92 413161 unboosted Sisonke participants, rVE of the booster was 59% (95%CI 29-76%) 93 against SARS-CoV-2 infection: 77% (95%CI 9–94%) in the one-Ad26.COV2.S dose group 94 and 52% (95%CI 13-73%) in the two-dose group. Severe COVID-19 was identified in 148 95 unboosted participants, and only one SHERPA participant with severe HIV-related 96 immunosuppression. Of 11798 participants in the safety analysis, 271 (2.3%) reported a 97 reactogenicity event or unsolicited AE, more among those with prior SARS-CoV-2 infections 98 (adjusted odds ratio [aOR] 2.03, 95%CI 1.59-2.59) and less among people living with HIV 99 (PLWH) (aOR 0.49, 95%CI 0.34-0.69). No related serious AEs were reported. In an 100 immunogenicity sub-study, mRNA-1273 increased antibody functions and T-cell responses 4 101 weeks after boosting regardless of the number of prior Ad26.COV2.S doses, or HIV status, 102 and generated Omicron spike-specific cross-reactive responses. mRNA-1273 boosters after 103 one or two Ad26.COV2.S doses were well-tolerated, safe and effective against Omicron 104 SARS-CoV-2 infections among HCWs and PLWH.

105

Trial Registration: The SHERPA study is registered in the Pan African Clinical Trials

107 Registry (PACTR): PACTR202310615330649 and the South African National Clinical Trial

108 Registry (SANCTR): DOH-27-052022-5778.

109

110 INTRODUCTION

111 During the first 2 years of the COVID-19 pandemic, populations in low- and middle-income

112 countries (LMICs) had limited access to mRNA vaccines. Instead, most LMICs including

113 South Africa, started their vaccination programmes with vector-based vaccines, such as

114 Ad26.COV2.S (Janssen/Johnson & Johnson) and ChAdOx1-S (Oxford/AstraZeneca). When

115 vaccine demand subsided in high-income countries and production increased, mRNA

vaccines by Pfizer-BioNTech and Moderna became available, allowing for a heterologous

boosting strategy in LMICs. While this strategy was supported by immunogenicity data and

by programmatic evaluations^{1,2}, it was not formally investigated in clinical trials, meaning

there was limited evidence on safety and effectiveness of mRNA booster vaccinations after

the Ad26.COV2.S vaccine, especially from LMICs with high HIV prevalence.

121

In South Africa, the COVID-19 vaccination rollout started in February 2021, when half a
million healthcare workers received a single dose of Ad26.COV2.S in the Sisonke phase 3b

implementation trial³, just before the rapid spread of the SARS-CoV-2 Delta variant. Through

125 monitoring of national COVID-19 databases, Sisonke showed that a single dose of

126 Ad26.COV2.S was 67% (95% confidence interval [CI] 62–71%) effective against COVID-19-

related hospitalisations and 83% (75–89%) against COVID-19-related deaths³. Following the

release of the ENSEMBLE 2 trial results^{4,5}, approximately half of the Sisonke participants

129 opted for a second Ad26.COV2.S dose between October and December 2021. By this time,

130 South Africa experienced a surge in SARS-CoV-2 cases with the Omicron variant. Early data

131 showed that the second Ad26.COV2.S dose provided added protection against

hospitalizations and deaths during the Omicron wave 6 .

133

134 Following the recommendation by the United States Food and Drug Administration to limit

the use of the Ad26.COV2.S vaccine, because of rare reported events of thrombosis with

136 thrombocytopenia syndrome, and emerging data showing superior neutralizing antibody

137 responses after mRNA vaccines, there was an urgent need to clarify the safety,

immunogenicity and effectiveness of a heterologous vaccination approach in LMICs.

- 139 Considering this, the Sisonke study team rapidly implemented and conducted the SHERPA
- 140 study nested in Sisonke to investigate a heterologous mRNA-1273 boost after one or two

141 doses of Ad26.COV2.S among healthcare workers in South Africa.

142

143

144 METHODS AND MATERIALS

145 Study design and setting

146 SHERPA (<u>Sisonke He</u>terologous m<u>R</u>NA-1273 boost after <u>P</u>rime with <u>A</u>d26.COV2.S) was a

single-arm, open-label, phase 3 study, nested in the Sisonke trial, in which healthcare

148 workers in South Africa had received one or two doses of Ad26.COV2.S between February

and December 2021. In SHERPA, Sisonke participants were offered a mRNA-1273 booster

dose (ancestral strain) at 30 clinical research sites (CRS) across South Africa, between 23

151 May 2022 and 12 November 2022. Using routinely collected national data, we aimed to

152 compare SARS-CoV-2 infections and COVID-19-related hospitalizations and deaths among

153 SHERPA participants with Sisonke participants who did not receive the mRNA-1273 booster

154 (see study schema in **Supplementary Table 1**). The data cut-off for outcome ascertainment

155 was 31 December 2022. Seven CRS followed 200 SHERPA participants for six months in a

- safety and immunogenicity sub-study. SHERPA was registered in the Pan African Clinical
- 157 Trials Registry (PACTR202310615330649) and the South African National Clinical Trial
- 158 Registry (DOH-27-052022-5778). All participants provided written informed consent.
- 159

160 Participants

161 Sisonke participants were invited to join SHERPA via short messaging system (SMS) with a 162 study website link, where they could register and choose a convenient CRS. SHERPA 163 participants were 18 years or older with or without comorbidities, including HIV infection, 164 were employed in the South African public or private healthcare sector, and had received 165 either one or two doses of Ad26.COV2.S in Sisonke. Considering the high COVID-19 166 morbidity among pregnant women, pregnant and breastfeeding women were eligible. 167 Sisonke participants who had received any COVID-19 vaccine other than one or two doses 168 of Ad26.COV2.S (e.g., another mRNA booster) and those with evidence of SARS-CoV-2 169 infection within 14 days of enrolment were excluded (see Supplementary Table 2 for full 170 eligibility criteria).

171

172 Study procedures

Once consented, the study team took a medical history, conducted a physical examination, and recorded any concomitant medications. Female participants of reproductive age had a pregnancy test, and all participants had a nasal swab taken for SARS-CoV-2 polymerase chain reaction (PCR) testing and a plasma sample to test for SARS-CoV-2 serology before vaccination. Participants in the safety and immunogenicity sub-study also had peripheral blood mononuclear cells (PBMC) and plasma samples taken before mRNA-1273 booster vaccination and 4 and 24 weeks after vaccination (see **Supplementary Tables 3 and 4**).

181 The 50mcg dose of the mRNA-1273 booster was prepared by research pharmacists. Clinical 182 research staff then administered the vaccine in the deltoid muscle, and participants were 183 monitored for 15 minutes for immediate reactogenicity events or allergic reactions. Adverse 184 events (AE) experienced at the vaccination visit were managed and recorded by the CRS 185 team. After the observation period, participants were issued with vaccination certificates, and 186 CRS and Sisonke 'Safety Desk' contact details for AE reporting. Pregnant and breastfeeding 187 women were followed up by the central safety team, through a pregnancy and breastfeeding 188 registry that both the CRS and safety teams had access to.

189

190 Immunogenicity sub-study

191	Plasma and PBMC samples were taken before mRNA-1273 vaccination and 4 and 24 weeks
192	after vaccination. We conducted SARS-CoV-2 spike enzyme linked immunosorbent assays
193	(ELISA), SARS-CoV-2 nucleocapsid ELISA testing, a lentiviral pseudovirus neutralization
194	assay, and an antibody-dependent cellular cytotoxicity (ADCC) assay at all timepoints.
195	Neutralizing antibody responses in people living with HIV (PLWH) were tested using a
196	vesicular stomatitis virus-based neutralization assay which was not subject to antiretroviral
197	therapy interference ⁷ , and which produced equivalent titers to the lentiviral assay
198	(Supplementary Fig.1). T-cell responses to SARS-CoV-2 spike were measured from
199	cryopreserved PBMC using intracellular cytokine staining and flow cytometry. This was
200	performed on the first 50 participants with available PBMC samples at the three sampling
201	visits (see Supplementary materials for immunogenicity assays).
202	
203	Data sources and data management

205 was built for Sisonke (**Supplementary Fig.2**). Data sources included the Notifiable Medical

206 Conditions Sentinel Surveillance (NMCSS) database of SARS-CoV-2 cases, the DATCOV

207 database of reported confirmed COVID-19 hospital admissions, and the national Electronic

208 Vaccination Data System (EVDS) for COVID-19 vaccines. Automated near real-time

209 deterministic and probabilistic linkage algorithms were applied to link these three routine

210 COVID-19 datasets. Breakthrough SARS-CoV-2 infections, defined as a positive SARS-

211 CoV-2 PCR or antigen test ≥14 days after booster vaccination, and COVID-19

212 hospitalisations or deaths were identified through linking the databases.

213

SHERPA study visits were recorded in a Research Electronic Data Capture (REDCap)

215 database (Vanderbilt University, Nashville, US). After the screening/enrolment visit, solicited

and unsolicited AEs were self-reported via an online data entry link shared by SMS with

- 217 participants 1, 7 and 28 days after the booster. All safety events including Serious AEs
- 218 (SAE) and AEs of Special Interest (AESI) were reviewed by safety clinicians and the
- 219 Protocol Safety Review Team (PSRT). Data management systems were CFR Part 11 and
- 220 POPIA compliant and processes followed Good Clinical Data Management Processes
- 221 guidance.
- 222
- 223 Variables
- 224 For the relative vaccine effectiveness (rVE) analysis, we used demographic and clinical
- variables that are routinely collected in the EVDS, including age, sex, common
- 226 comorbidities, and geographic location. The NMCSS database provided information about
- 227 previous SARS-CoV-2 infections.
- 228
- 229 Outcomes
- 230 The co-primary outcomes were to assess the rVE of the mRNA-1273 booster by comparing
- the rates of SARS-CoV-2 infections and severe COVID-19 cases (defined as COVID-19
- 232 hospitalizations or deaths) among SHERPA participants compared to unboosted Sisonke
- 233 participants. Secondary outcomes included an assessment of rVE of the mRNA-1273
- 234 booster against SARS-CoV-2 Infections, COVID-19 hospitalizations and deaths, in those
- who had received one or two doses of Ad26.COV2.S separately; an assessment of safety of
- the mRNA-1273 boost, including among pregnant women and PLWH; and comparisons of
- antibody and T-cell responses before and after vaccination.
- 238

239 Statistical analysis

- Analyses for the primary and secondary outcomes were performed using SAS version 9.4
- 241 (Statistical Analysis Software, North Carolina, USA) and Stata version 17 (College Station,
- 242 TX, USA). Demographic and clinical data of participants enrolled in SHERPA and Sisonke
- 243 were summarized using descriptive statistics including frequencies, proportions, and
- 244 medians with interquartile ranges (IQR). For the primary analysis, we used a statistical

²⁴⁵ method proposed by Fintzi and Follmann⁸ referred to here as an adjusted cohort approach,

246 which allowed inclusion of SHERPA participants within the larger Sisonke cohort

- 247 (Supplementary Fig.3).
- 248

249 We used a Cox regression model with the mRNA-1273 booster status as a time-varying 250 covariate, adjusting for age, sex, an indicator of whether a participant had previously 251 received one or two doses of Ad26.COV2.S, geographic location, number of comorbidities 252 and evidence of prior SARS-CoV-2 infection. This time-varying exposure was characterized 253 by a continuous piecewise linear function of time elapsed since the first mRNA-1273 dose 254 (23 May 2022) for the log hazard ratio. Participants who did not experience an event of 255 interest were censored on 31 December 2022 (cut-off date). The rVE in reducing the risk of 256 SARS-CoV-2 infection and COVID-19 hospitalizations and deaths was estimated as one 257 minus the estimated hazard ratio with 95% CI. Further details regarding outcome analyses, 258 including an alternative matched cohort analysis approach, definitions of variables, and 259 immunogenicity analyses are detailed in the Statistical Analysis Plan. 260

261 Study approvals

262 The SHERPA and Sisonke trial protocols were approved by the South African Health 263 Products Regulatory Authority (SAHPRA), and health research ethics committees of all 264 participating CRSs. The study received full ethical approval by the following ethics 265 committees in South Africa: Pharma-Ethics, Stellenbosch University Health Research Ethics 266 Committee, University of KwaZulu-Natal Biomedical Research Ethics Committee, University 267 of Cape Town Human Research Ethics Committee, Sefako Makgatho University Research 268 Ethics Committee, The South African Medical Research Council Human Research Ethics 269 Committee and the University of the Witwatersrand Human Research Ethics Committee. 270

- 271
- 272

273 **RESULTS**

274 Study Population

- 275 Of 501230 Sisonke participants who had received one or two Ad26.COV2.S doses between
- 276 17 February 2021 and 22 May 2022, 12342 enrolled into SHERPA and received the mRNA-
- 277 1273 booster between 23 May 2022 and 12 November 2022 (Fig.1). Of these, 1094 (8.9%)
- 278 were excluded from the rVE analysis, because they had either received a third
- 279 Ad26.COV2.S or a BNT162b2 mRNA booster, or had received an Ad26.COV2.S vaccine
- after the earliest date of mRNA-1273 vaccination on 23 May 2022. Participants at one CRS
- had to be excluded from rVE and safety analyses due to concerns about data integrity. The
- 282 mRNA-1273 booster rVE analysis included 11248 SHERPA participants, of whom 5102
- 283 (45.4%) had received one and 6146 (54.6%) two prior Ad26.COV2.S doses. These were
- compared to 413161 non-SHERPA Sisonke participants, of whom 185676 (44.9%) had

285 received one and 227485 (55.1%) two doses of Ad26.COV2.S.

286

Figure 1: Flow Chart of the SHERPA Analysis Cohort nested in the Sisonke

288 Implementation Trial

- 289
- 290 Baseline demographic and clinical characteristics of the SHERPA and non-SHERPA
- 291 participants stratified by number of previous Ad26.COV2.S vaccinations are summarized in
- 292 **Table 1**. The majority (79.3%) of SHERPA participants were female and median age was 41
- 293 years (IQR 35–48). One third (32.2%) of participants reported at least one comorbidity, most
- commonly HIV infection (18.7%), hypertension (12.9%) and diabetes (4.6%). Participants
- 295 were recruited from all nine South African provinces. Non-SHERPA participants had similar
- characteristics, apart from fewer reporting HIV infection (8.3%).
- 297
- 298
- 299

300 Table 1: Baseline Demographics and clinical Characteristics of SHERPA and non-

301 SHERPA Participants previously vaccinated in Sisonke

		SHERPA		non-SHERPA			
Characteristic	mRNA-1273	2 Ad26.COV2.S + mRNA-1273 (N=6146)	Total (N=11248)	Ad26.COV2.S (N=185676)	2 Ad26.COV2.S (N=227485)	Total (N= 413161)	
Sex, n (%)	I				1		
Female	4048 (79.3%)	4877 (79.4%)	8925 (79.3%)	136534 (73.5%)	171854 (75.5%)	308388 (74.6%)	
Male	1054 (20.7%)	1269 (20.6%)	2323 (20.7%)	49142 (26.5%)	55631 (24.5%)	104773 (25.4%)	
Median age (years), IQR	40 (33-46)	43 (36-50)	41 (35-48)	40 (33-49)	44 (35-53)	42 (34-51)	
Age groups (y	ear), n (%)						
18-39	2538 (49.7%)	2297 (37.4%)	4835 (43.0%)	90048 (48.5%)	83720 (36.8%)	173768 (42.1%)	
40-49	1743 (34.2%)	2288 (37.2%)	4031 (35.8%)	53390 (28.8%)	68471 (30.1%)	121861 (29.5%)	
50-59	699 (13.7%)	1257 (20.5%)	1956 (17.4%)	31549 (17.0%)	53257 (23.4%)	84806 (20.5%)	
≥60	122 (2.4%)	304 (4.9%)	426 (3.8%)	10628 (5.7%)	22034 (9.7%)	32662 (7.9%)	
Missing	0	0	0	61 (<0.1%)	3 (<0.1%)	64 (<0.1%)	
Number of cor	l norbidities, n (%))					
0	3573 (70.0%)	4048 (65.9%)	7621 (67.8%)	141683 (76.3%)	166384 (73.1%)	308067 (74.6%)	
1	1334 (26.1%)	1792 (29.2%)	3126 (27.8%)	37390 (20.1%)	50328 (22.1%)	87718 (21.2%)	
≥2	195 (3.8%)	304 (4.9%)	501 (4.5%)	6603 (3.6%)	10773 (4.7%)	17376 (4.2%)	
Risk factors fo	or severe COVID	-19, n (%)					
Living with HIV	977 (19.1%)	1122 (18.3%)	2099 (18.7%)	17612 (9.5%)	16572 (7.3%)	34184 (8.3%)	
Hypertension	541 (10.6%)	912 (14.8%)	1453 (12.9%)	23007 (12.4%)	38094 (16.7%)	61101 (14.8%)	
Diabetes	188 (3.7%)	332 (5.4%)	520 (4.6%)	8382 (4.5%)	14471 (6.4%)	22853 (5.5%)	
Cancer	5 (0.1%)	15 (0.2%)	20 (0.2%)	355 (0.2%)	680 (0.3%)	1035 (0.3%)	
Tuberculosis	10 (0.2%)	12 (0.2%)	22 (0.2%)	236 (0.1%)	209 (0.1%)	445 (0.1%)	
Heart disease	9 (0.2%)	26 (0.4%)	35 (0.3%)	974 (0.5%)	1661 (0.7%)	2635 (0.6%)	
Chronic lung disease	5 (0.1%)	14 (0.2%)	19 (0.2%)	481 (0.3%)	901 (0.4%)	1382 (0.3%)	
Geographical	location, n (%)	II			1		
Eastern Cape	762 (14.9%)	838 (13.6%)	1600 (14.2%)	25454 (13.7%)	24773 (10.9%)	50227 (12.2%)	
Free State	209 (4.1%)	308 (5.0%)	517 (4.6%)	8123 (4.4%)	11926 (5.2%)	20049 (4.9%)	
Gauteng	1884 (36.9%)	1918 (31.2%)	3802 (33.8%)	51952 (28.0%)	61629 (27.1%)	113581 (27.5%)	
KwaZulu-Natal	1255 (24.6%)	1464 (23.8%)	2719 (24.2%)	41449 (22.3%)	39044 (17.2%)	80493 (19.5%)	

Limpopo	63 (1.2%)	93 (1.5%)	156 (1.4%)	11188 (6.0%)	17517 (7.7%)	28705 (6.9%)
Mpumalanga	227 (4.4%)	187 (3.0%)	414 (3.7%)	10140 (5.5%)	9107 (4.0%)	19247 (4.7%)
North West	184 (3.6%)	213 (3.5%)	397 (3.5%)	9073 (4.9%)	10875 (4.8%)	19948 (4.8%)
Northern Cape	4 (0.1%)	1 (0.0%)	5 (0.0%)	3251 (1.8%)	4701 (2.1%)	7952 (1.9%)
Western Cape	514 (10.1%)	1124 (18.3%)	1638 (14.6%)	25046 (13.5%)	47913 (21.1%)	72959 (17.7%)

302

303

312

313

314

315

316

317

318

319

320

321

322

323

324

304 Prior SARS-CoV-2 infections and time since last vaccination

305 Participants were checked against the NMCSS database for evidence of previous SARS-

306 CoV-2 infection. Among SHERPA participants 1079 (9.2%) had evidence of a previous

307 SARS-CoV-2 infection compared to 54770 (13.3%) among the non-SHERPA group. Overall,

these estimates were likely an underestimate considering higher self-report rates (28%) and

309 evidence of high prevalence of baseline seropositivity in the immunogenicity sub-study. The

310 median days between the last Ad26.COV2.S dose and 23 May 2022 (SHERPA start) was

188 days (IQR 171-419) among SHERPA participants and 189 days (IQR 172-406) among

the non-SHERPA group (Table 2).

325 Table 2: Recorded prior COVID-19 Infections among SHERPA and non-SHERPA

326 Participants nested in the Sisonke Study

		SHERPA			non-SHERPA	
	Ad26.COV2.S + mRNA-1273	2 Ad26.COV2.S + mRNA-1273	Total (N=11248)	Ad26.COV2.S (N=185676)	2 Ad26.COV2.S (N=227485)	Total (N= 413161)
Characteristic	(N=5102)	(N=6146)	(N=11240)	(14=105070)	(11=227403)	(14= 413101)
Documented previous SARS- CoV-2 infection*	398 (7.8%)	629 (10.2%)	1027 (9.2%)	21480 (11.6%)	33290 (14.6%)	54770 (13.3%)
Recent prior infection [#]	20 (0.4%)	77 (1.2%)	97 (0.9%)	2422 (1.3%)	6945 (3.1%)	9367 (2.3%)
Non-recent prior infection ⁺	378 (7.4%)	552 (9.0%)	930 (8.3%)	19058 (10.3%)	26345 (11.6%)	45403 (11.0%).
Days between las (SHERPA group)					eiving the mRNA-	1273
Median, IQR			188 (171 -			189 (172 -

Median, IQR			188 (171 -			189 (172 -
	424 (382 - 443)	172 (153 - 181)		418 (378 - 437)	173 (159 - 182)	
			419)			406)

327

328 *Infection on or before 23 May 2022; Both PCR and antigen tests considered.

 * Recent infection means less \leq 90 days before enrollment for SHERPA participants and < 90 days

330 before SHERPA study start 23 May 2022 for non-SHERPA participants.

⁺Non- recent infection means less > 90 days before enrollment for SHERPA participants and > 90

days before non-SHERPA participants study start 23 May 2022 for non-SHERPA participants.

333

334 SARS-CoV-2 infection and severe COVID-19 endpoints

As of 31 December 2022, after 3056 person-years of follow up, there were 13 recorded

336 SARS-CoV-2 infections among SHERPA participants at median 125 days (IQR 90-154) after

337 mRNA-1273 boosting. In contrast, 3352 infections were recorded among the non-SHERPA

group after 251104 years of follow-up (Supplementary Table 5). There were 148 COVID-19

hospitalization or deaths among the non-SHERPA group compared to one among SHERPA

340 participants. This immunocompromised PLWH, with a CD4 count of less than 200 cells/mm³

- and high HIV viremia, died of COVID-19 pneumonia with respiratory distress syndrome, six
- 342 months after receiving the mRNA-1273 booster.
- 343
- 344 Relative vaccine effectiveness of the mRNA-1273 booster
- 345 Comparing SHERPA participants to the non-SHERPA group, the unadjusted analysis
- 346 showed a rVE of 59% (95%CI 29-76%) against SARS-CoV-2 infection, which did not change
- 347 after adjusting for age, sex, prior SARS-CoV-2 infection, prior vaccination and geographic
- location (**Table 3**). The adjusted rVE of the booster among participants who had one prior
- 349 Ad26.COV2.S dose was 77% (95%Cl 9-94%) and 52% (95%Cl 13-73%) for those who had
- two prior Ad26.COV2.S doses. In a separate model adjusting for HIV the rVE estimate only
- 351 slightly changed to 57% (95%CI 25-75%). With only one severe COVID-19 case among
- 352 SHERPA participants and few severe endpoints overall, the rVE estimate for COVID-19
- hospitalizations and deaths lacked precision (**Supplementary Table 6**). In the alternative
- 354 matched cohort analysis, the overall rVE against SARS-CoV-2 infection was slightly higher
- 355 at 63% (95%Cl 32-82%) (Supplementary Tables 7 and 8).
- 356

357 Table 3: Relative Vaccine Effectiveness of mRNA-1273 Booster against SARS-CoV-2

358 Infection

	Unadjusted	Adjusted*: Model with comorbidities
	VE (95% CI)	VE (95% CI)
	Primary Endpoint	-
SARS-CoV-2 Infection	59% (29 -76%)	59% (29 - 76%)
	Secondary Endpoints	
SARS-CoV-2 infections after 1 previous Ad26.COV2.S	77% (8 - 94%)	77% (9 - 94%)
SARS-CoV-2 infections after 2	51% (13 - 73%)	52% (13 - 73%)
previous Ad26.COV2.S		

359

360 *Adjusted for age, sex, prior COVID, prior vaccination, geographical location

С	c	1
Э	σ	т

362 Safety profile of mRNA-1273 booster

502	
363	Of 11798 SHERPA participants included in the safety analysis, 228 (1.9%) participants
364	reported 575 reactogenicity events within 7 days after the mRNA-1273 booster. Of these,
365	230/575 (40%) were local reactogenicity events including 97/230 (42.2%) injection site pain,
366	69/230 (30%) swelling, 32/230 (13.9%) induration and 32/230 (13.9%) erythema events. A
367	total of 345 systemic reactogenicity events were reported including 123 (35.7%) malaise
368	and/or myalgia, 120 (34.8%) headache, 66 (19.1%) fever, 17 (4.9%) chills, 10 (2.9%)
369	nausea, 5 (1.4%) vomiting and 4 (1.2%) arthralgia. All reported local and systemic
370	reactogenicity were mild or moderate (grade 1 or 2) and all resolved without sequalae.
371	
372	Unsolicited AEs collected for 28 days after vaccination and those meeting SAE/AESI criteria
373	collected until the end of study participation were reported by 98 (0.8%) participants,
374	reporting a total of 115 events. Of these events, 17 events met SAE criteria. Three of the 17
375	SAEs also met AESI criteria, the other 4 AESIs were grade 1 and 2 anosmia and ageusia,
376	which resolved without sequalae. No related SAEs were reported during the study.
377	
378	More reactogenicity events were reported by participants with prior SARS-CoV-2 infection
379	(3.6% vs 1.8%), HIV-negative status (2.7% vs 1.2%) and those who received two compared
380	to one prior Ad26.COV2.S dose (2.6% vs 2.0%). In a logistic regression model adjusting for
381	age and sex, a prior SARS-CoV-2 infection (adjusted odds ratio [aOR] =2.03, 95%Cl 1.59-
382	2.59) and an HIV positive status (aOR=0.49, 95%CI 0.34-0.69) were associated with
383	local/systemic reactions, but not having received two versus one Ad26.COV2.S dose before
384	the mRNA-1273 booster (aOR=1.26, 95%CI 0.99-1.62), Supplementary Table 9.
205	

385

Among 70 confirmed pregnancies, there were 39 (55.7%) full-term births, 4 (5.7%) preterm

births (<37 weeks gestation), 11 (15.7%) early miscarriages (<12 weeks gestation), 7

388 (10.0%) stillbirths (>20 weeks gestation), and one (1.4%) ectopic pregnancy. Six (8.6%)

women opted for an elective termination of pregnancy and two (2.9%) were lost to follow-up.
All adverse outcomes, including miscarriages, preterm births and stillbirths were evaluated
and deemed unrelated to vaccination by CRS investigators and the PSRT. Preterm births
were reported in women with hypertension in pregnancy and multiple gestations, while the
stillbirths (experienced by women aged 32 to 44 years) were evaluated as associated with
abruptio placenta, postdate, cord around the fetal neck, and complicated home delivery

- 395 (Supplementary Table 10).
- 396

397 Immune responses after mRNA-1273 booster

398 Baseline neutralizing antibody titers were 2-3 fold higher in participants who had received 2 399 doses versus 1 dose of Ad26.COV2.S (median: 1311 vs 3269 for D614G and 508 vs 1281 400 for BA.4) (Fig. 2A,B). The mRNA-1273 boost resulted in increased neutralizing antibodies 401 titers for D614G after 4 weeks and then a decline by 24 weeks among those with one and 402 two doses of Ad26.COV2.S (median baseline, 4-week and 24-week titers of 1311, 7033 and 403 2220 for the 1-dose group and 3269, 17653, 5526 for the 2-dose group), Fig. 2A-C. The 404 antibody response after boosting was less pronounced towards the BA.4 pseudovirus 405 despite a significant increase in rVE against this variant of concern. Baseline spike-binding 406 antibody titers were comparable regardless of the number of previous Ad26.COV2.S doses. 407 Binding titers significantly increased up to 6-fold 4 weeks post-boost (Fig. 2D,E), while 408 ADCC had smaller but significant increases post-boost (Fig. 2F,G). The binding and ADCC 409 titers were lower 6 months after the boost, with similar titers observed between both 410 Ad26.COV2.S groups (Fig. 2D-G). At baseline, PLWH had up to 3-fold lower binding 411 antibody titers and up to 2-fold lower neutralizing activity against D614G compared to HIV 412 negative participants, irrespective of prior Ad26.COV2.S doses, while ADCC levels were 413 similar (Supplementary Fig.4). Antibody functions in PLWH followed similar trends after the 414 booster as HIV-negative participants.

415

416

417 Figure 2: Antibody Response elicited after mRNA-1273 heterologous Boost

418 Legend: Plasma from a subset of participants were assessed to determine the antibody 419 response elicited upon heterologous boost (mJnJ) after 1 Ad26.COV2.S dose (JnJ x1; n=19) 420 or 2 Ad26.COV2.S doses (JnJ x2; n=29). The neutralization activity was measured using a 421 SARS-CoV-2 pseudovirus-based neutralization assay with (panel A) D614G, (panel B) 422 Omicron BA.4 and (panel C) D614G in people living with HIV (PLWH). The plasma 423 neutralization titer is measured as an ID_{50} . Black horizontal bars represent medians. The 424 threshold of detection for the neutralization assay is an ID_{50} of 20. Antibody binding was 425 measured using an in-house SARS-CoV-2 assay using the D614G full spike protein (panel D 426 and E). An EC50 was used to measure the binding titers of the samples. ADCC activity was 427 measured by detecting the crosslinking ability of the antibodies present in the serum (panel 428 F and G). Relative light units were measured which correlate with the levels of FcyRIIIa 429 signalling. For all assays, statistical significance was measured with the Kruskal-Wallis test 430 with Dunn's multiple comparisons test. Significance is shown as: p < 0.05, p < 0.01, 431 0.001 and ****p < 0.0001. Medians and fold changes are depicted under each graph. 432 Samples were run in duplicate for all assays. Nucleocapsid ELISA was used to identify prior 433 SARS-CoV-2 infections. Only individuals who were seropositive at baseline were included in 434 the analysis as there was only 1 nucleocapsid-seronegative participants in the JnJ x1 group.

435

436 We examined T-cell responses in a subset of 50 participants (Fig. 3A). At baseline, spike-437 specific CD4+ T-cell responses were detected in 96% of participants (Fig. 3B). Four weeks 438 after mRNA-1273 boosting, the frequency increased 2-fold (median: 0.074% vs 0.169%, 439 p<0.0001), followed by contraction to a median of 0.113% by 24 weeks, which was not 440 significantly different from baseline. Spike-specific CD8+ T-cell responses occurred in 52% 441 of participants at baseline, and followed a similar trajectory as CD4 responses, increasing 442 significantly at 4 weeks (median: 0.034% vs 0.057%, p=0.0029; Fig. 3C) and waning to 443 0.047% by 24 weeks. When examining the effect of prior vaccination with Ad26.COV2.S 444 (Fig. 3D), there were significantly higher CD4+ responses at baseline in those who received

445 two compared to one prior dose, which persisted at all timepoints after mRNA-1273 446 boosting. In contrast, the magnitude of CD8+ responses was similar between those who received one or two Ad26.COV2.S doses. HIV infection had no negative impact on vaccine 447 448 booster responses at 4 or 24 weeks (Fig. 3E). When examining T-cell cross-reactivity to 449 Omicron sub-lineages, we observed a high degree of preservation of the T-cell responses to 450 Omicron BA.1, BA.4/5 and XBB.1 (Fig. 3F-G). 451 452 Figure 3: T-cell Response elicited after mRNA-1273 heterologous Boost 453 Legend: (A) Clinical characteristics of the T-cell sub-study cohort. Frequency of spike-454 specific CD4+ (B) and CD8+ (C) T-cells producing any of the measured cytokines (IFN- γ , IL-455 2 or TNF- α) in response to stimulation with a peptide pool spanning ancestral spike protein 456 at baseline (BL), week 4 (W4) and week 24 (W24), in participants vaccinated with one or two 457 prior doses of Ad26.COV2.S and an mRNA-1273 booster. The median response and 458 proportion of participants with a spike-specific CD4+ or CD8+ T-cell responses are indicated 459 below the graphs. (D) Spike-specific CD4+ and CD8+ T-cell cytokine responses stratified 460 according to number of Ad26.COV2.S doses received. (E) Spike CD4+ and CD8+ T-cells in 461 HIV-uninfected participants (pink) or PLWH (red). (F) Spike-specific CD4+ T-cell responses 462 to spike from ancestral virus and Omicron sub-lineages BA.1, BA.4/5 and XBB.1. (G) Fold 463 change of Omicron sub-lineage responses compared to ancestral spike. Bars represent the 464 medians. Differences between responses at different time points post boost were assessed 465 using a two-tailed Wilcoxon paired test. Differences between participants vaccinated with 466 one or two doses of Ad26.COV2.S and responses to different SARS-CoV-2 variants were 467 calculated using a Mann-Whitney U test. The number of participants included in each 468 analysis is indicated on the graphs. 469 470

.....

471

472 DISCUSSION

473	Nested in the Sisonke phase 3b implementation study, the SHERPA trial showed that one
474	mRNA-1273 booster administered after 1 or 2 doses of Ad26.COV2.S was safe and well
475	tolerated regardless of HIV status, comorbidities or prior SARS-CoV-2 infection. The mRNA-
476	1273 booster had a rVE of 59% (29-76%) in preventing SARS-CoV-2 infections overall, 77%
477	(9-94%) after one Ad26.COV2.S dose and 52% (13-73%) after 2 Ad26.COV2.S doses up to
478	7 months after the boost. Breakthrough infections occurred during the Omicron wave
479	(Supplementary Fig. 5), thus the data confirm the benefit of heterologous mRNA-1273
480	boosting after priming with Ad26.COV2.S against Omicron sub-lineages.
481	
482	The additional benefit of the mRNA-1273 booster was particularly high among participants
483	who had only received a single Ad26.COV2.S previously, also indicating that the booster
484	was especially effective among those who had received their vaccine dose more than a year
485	previously. This finding also corroborated with strong antibody and T-cell immune responses
486	elicited by the booster in the immunogenicity sub-study. Consistent with epidemiological data
487	on the evolving COVID-19 pandemic, few severe COVID-19 cases were detected in the
488	Sisonke cohort and only a single case among SHERPA participants, thereby not providing
489	sufficient statistical power for a meaningful interpretation of rVE against COVID-19
490	hospitalizations and deaths.
491	

491

Our findings for heterologous boosting corroborate with studies reporting on homologous mRNA-1273 boosting in the USA. In one study the rVE of a homologous mRNA-1273 boost against SARS-CoV-2 infection was 61% (95%CI 60–62%) among immunocompetent adults receiving the booster ≥150 days after priming during the Omicron wave⁹. In a second study amongst US veterans receiving a third homologous mRNA-1273 booster during the Omicron wave, the rVE was 64% (95%CI 63-65%) compared with a rVE of 12% (95%CI 10-15%) for 2-dose vaccination¹⁰.

499

500	Earlier in the pandemic, studies assessed the VE of a heterologous prime-boost approach.
501	One study from Sweden with 16402 participants receiving ChAdOx1 nCoV-19 prime
502	followed by a mRNA-1273 boost found a VE of 79% (95%CI, 62-88%) against symptomatic
503	COVID-19 infection compared with unvaccinated controls during the Delta wave ¹¹ . An almost
504	identical rVE was found in a study conducted across emergency departments in the USA for
505	people who received a single Ad26.COV2.S dose followed by a mRNA-1273 boost ¹² .
506	
507	Our findings indicate that in LMICs where vaccine availability has been limited and HIV
508	prevalence, co-morbidities and prior SARS-CoV-2 infection are high, a heterologous mRNA-
509	1273 boost, using ancestral vaccine after one or two Ad26.COV2.S vaccinations was
510	protective against SARS-CoV-2 infection in healthcare workers during the Omicron wave.
511	Our data also confirms the safety of an mRNA-1273 boost after Ad26.COV2.S priming
512	amongst healthcare workers, including PLWH, people with comorbidities and pregnant
513	women.
514	
515	Previous epidemiological studies on pregnancy outcomes and placental studies have shown
516	that mRNA vaccines are safe in pregnancy and that there is negligible uptake and
517	inflammatory responses within placental tissues post vaccination ^{13,14,15} . In South Africa, only
518	68.3% of pregnant women have their first antenatal visit before 20 weeks gestation ¹⁶ ,
519	meaning that national data on early pregnancy losses are limited. However, early pregnancy
520	losses observed in SHERPA (15.7%) were comparable to other clinical trial cohorts (6.1-
521	17.9%), which included early pregnancy testing and pregnancy outcome tracking ^{17,18} .
522	Stillbirths reported in this study (10.0%) were associated with polymorbid conditions,
523	including abruptio placenta, cord round the fetal neck and postdate, that provided clear
524	alternative causes to the occurrence of the events. While the stillbirth rate was higher than in
525	two clinical trial cohorts among younger, HIV negative women in HIV vaccine trials (1.5-
526	3.5%), our data are in keeping with a 10% increase in stillbirths noted nationally in recent

review periods¹⁹, as well as the generally higher stillbirth rates reported among older cohorts
 and cohorts of PLWH^{20,21,22}.

529

530	Antibody responses were higher among participants with two compared to one prior
531	Ad26.COV2.S dose and were boosted with a heterologous mRNA vaccine among both
532	groups, as reported previously ^{2,23,24} . Despite some evidence that Ad26.COV2.S may lead to
533	slower waning of immune responses than mRNA vaccines ^{25,26} , the decline of antibody
534	responses at 6 months in SHERPA suggests that the Ad26.COV2.S as a primary dose(s)
535	may not significantly increase the durability of mRNA-boosted antibody responses. Although
536	PLWH had lower antibody responses at baseline, mRNA-1273 boosting resulted in
537	comparable titers to HIV-negative participants. mRNA-1273 boosting increased spike-
538	specific T-cell responses, as described previously for heterologous vaccination regimens ^{2,27} .
539	These responses were durable and highly cross-reactive to Omicron sub-lineages.
540	
541	SHERPA had some limitations. First, it was a single arm trial nested in the larger Sisonke
542	trial. As in Sisonke, we relied on routinely collected data to ascertain COVID-19 endpoints.
543	However, this applied to both mRNA-1273 boosted and unboosted study groups, therefore
544	reducing the potential for reporting bias. Second, we observed too few severe COVID-19
545	endpoints to allow for a well-powered assessment of rVE against severe disease.
546	Contributing factors could have been that SHERPA was conducted during the Omicron
547	wave, when generally less severe disease was reported ²⁸ , South Africa has a high SARS-
548	CoV-2 seroprevalence of up to $80\%^{29}$, and all participants had at least received one dose of
549	Ad26.COV2.S previously. Finally, we were unable to compare pregnancy outcomes in the
550	SHERPA study with the larger Sisonke trial population, because pregnant women were
551	initially not eligible for Sisonke, and pregnancy outcomes were not systematically collected.
552	
553	Our data show that a heterologous mRNA-1273 boost following one or two Ad26.COV2.S

554 priming among healthcare workers including those with HIV, comorbidities and pregnancy

can be included in national policy. We also demonstrate that boosting with the ancestral
mRNA-1273 vaccine is still effective despite the evolution of SARS-CoV-2 into Omicron sublineage. This is important as variant vaccines may not be accessible in these settings. In
conclusion, the SHERPA trial showed a high rVE of the mRNA-1273 booster during the
Omicron wave among healthcare workers who had received one or two previous doses of
Ad26.COV2.S. The heterologous booster was safe and well tolerated, immunogenic and
effective in a LMIC with high HIV prevalence.

562

563 Declaration of Interests

564 KA and BL are employees of Moderna, Inc. and may hold stock/stock options in the

565 company. The other authors declare no conflict of interests.

566

567 Authorship contributions

568 **Conceptualization:** Nigel Garrett, Linda-Gail Bekker, Glenda E Gray, Ameena Goga

569 Data curation: Nigel Garrett, Azwidhwi Takalani, Annie Bodenstein, Phumeza Jonas, Imke

570 Engelbrecht, Waasila Jassat, Harry Moultrie, Debbie Bradshaw, Simone I. Richardson,

571 Millicent A. Omondi, Rofhiwa Nesamari, Roanne S. Keeton, Catherine Riou, Thandeka

572 Moyo-Gwete, Craig Innes, Zwelethu Zwane, Kathy Mngadi, William Brumskine, Nivashnee

573 Naicker, Disebo Potloane, Sharlaa Badal-Faesen, Steve Innes, Shaun Barnabas, Johan

Lombaard, Katherine Gill, Maphoshane Nchabeleng, Elizma Snyman, Friedrich Petrick,

575 Elizabeth Spooner, Logashvari Naidoo, Dishiki Kalonji, Vimla Naicker, Nishanta Singh,

576 Rebone Maboa, Pamela Mda, Daniel Malan, Anusha Nana, Mookho Malahleha, Philip

577 Kotze, Jon J. Allagappen, Andreas H. Diacon, Gertruida M. Kruger, Faeezah Patel, Penny L.

578 Moore, Wendy A. Burgers, Linda-Gail Bekker, Glenda E Gray, Ameena Goga

579 Formal analysis: Tarylee Reddy, Nonhlanhla Yende-Zuma, Azwidhwi Takalani, Ishen

580 Seocharan, Simone I. Richardson, Millicent A. Omondi, Rofhiwa Nesamari, Roanne S.

581 Keeton, Catherine Riou, Thandeka Moyo-Gwete, Penny L. Moore, Wendy A. Burgers

582 **Funding acquisition:** Nigel Garrett, Linda-Gail Bekker Glenda E Gray, Ameena Goga

583	Investigation: Nigel Garrett, Annie Bodenstein, Phumeza Jonas, Imke Engelbrecht, Simone
584	I. Richardson, Millicent A. Omondi, Rofhiwa Nesamari, Roanne S. Keeton, Catherine Riou,
585	Thandeka Moyo-Gwete, Craig Innes, Zwelethu Zwane, Kathy Mngadi, William Brumskine,
586	Nivashnee Naicker, Disebo Potloane, Sharlaa Badal-Faesen, Steve Innes, Shaun Barnabas,
587	Johan Lombaard, Katherine Gill, Maphoshane Nchabeleng, Elizma Snyman, Friedrich
588	Petrick, Elizabeth Spooner, Logashvari Naidoo, Dishiki Kalonji, Vimla Naicker, Nishanta
589	Singh, Rebone Maboa, Pamela Mda, Daniel Malan, Anusha Nana, Mookho Malahleha,
590	Philip Kotze, Jon J. Allagappen, Andreas H. Diacon, Gertruida M. Kruger, Faeezah Patel,
591	Penny L. Moore, Wendy A. Burgers, Linda-Gail Bekker, Glenda E Gray, Ameena Goga
592	Methodology: Nigel Garrett, Tarylee Reddy, Nonhlanhla Yende-Zuma, Waasila Jassat,
593	Harry Moultrie, Ishen Seocharan, Jackline Odhiambo, Penny L. Moore, Wendy A. Burgers,
594	Brett Leav, Linda-Gail Bekker, Glenda E Gray, Ameena Goga
595	Project administration: Nigel Garrett, Azwidhwi Takalani, Kubashni Woeber, Ishen
596	Seocharan, Jackline Odhiambo, Kentse Khuto, Kate Anteyi, Linda-Gail Bekker, Glenda E
597	Gray, Ameena Goga
598	Resources: Harry Moultrie, Penny L. Moore, Wendy A. Burgers, Kate Anteyi, Brett Leav,
599	Glenda E Gray
600	Supervision: Nigel Garrett, Azwidhwi Takalani, Penny L. Moore, Wendy A. Burgers, Linda-

- 601 Gail Bekker, Glenda E Gray, Ameena Goga
- 602 Validation: Tarylee Reddy, Nonhlanhla Yende-Zuma, Ishen Seocharan, Penny L. Moore,
- 603 Wendy A. Burgers
- 604 **Visualization:** Tarylee Reddy, Nonhlanhla Yende-Zuma, Ishen Seocharan, Simone I.
- Richardson, Millicent A. Omondi, Rofhiwa Nesamari, Roanne S. Keeton, Catherine Riou,
- 606 Thandeka Moyo-Gwete
- 607 Writing original draft: Nigel Garrett, Tarylee Reddy, Nonhlanhla Yende-Zuma, Thandeka
- 608 Moyo-Gwete, Penny L. Moore, Wendy A. Burgers, Ameena Goga
- 609 Writing review & editing: Nigel Garrett, Tarylee Reddy, Nonhlanhla Yende-Zuma,
- Azwidhwi Takalani, Kubashni Woeber, Annie Bodenstein, Phumeza Jonas, Imke

611 Engelbrecht, Waasila Jassat, Harry Moultrie, Debbie Bradshaw, Ishen Seocharan, Jackline 612 Odhiambo, Kentse Khuto, Simone I. Richardson, Millicent A. Omondi, Rofhiwa Nesamari, 613 Roanne S. Keeton, Catherine Riou, Thandeka Moyo-Gwete, Craig Innes, Zwelethu Zwane, 614 Kathy Mngadi, William Brumskine, Nivashnee Naicker, Disebo Potloane, Sharlaa Badal-615 Faesen, Steve Innes, Shaun Barnabas, Johan Lombaard, Katherine Gill, Maphoshane 616 Nchabeleng, Elizma Snyman, Friedrich Petrick, Elizabeth Spooner, Logashvari Naidoo, 617 Dishiki Kalonji, Vimla Naicker, Nishanta Singh, Rebone Maboa, Pamela Mda, Daniel Malan, 618 Anusha Nana, Mookho Malahleha, Philip Kotze, Jon J. Allagappen, Andreas H. Diacon, 619 Gertruida M. Kruger, Faeezah Patel, Penny L. Moore, Wendy A. Burgers, Kate Anteyi, Brett 620 Leav, Linda-Gail Bekker, Glenda E Gray, Ameena Goga 621 622 Funding 623 The SHERPA study was funded by Moderna, Inc. (Cambridge, Massachusetts, US) and the 624 South African Medical Research Council (SAMRC). Moderna provided mRNA-1273 free-of-625 charge. The Sisonke trial was funded by: The National Department of Health through

baseline funding to the SAMRC; the Solidarity Response Fund NPC; The Michael & Susan

627 Dell Foundation; the ELMA Vaccines and Immunization Foundation (21-V0001); and the Bill

628 & Melinda Gates Foundation (INV-030342). Moderna representatives reviewed the study

629 protocol, participated in safety oversight, and contributed as manuscript co-authors, but were

630 not involved in data collection and analysis.

631

632 Acknowledgements

We thank the participants, the protocol and safety teams, the site-Principal Investigators,

and their teams, the laboratory teams, SAHPRA, and the ethics committees for their

635 contribution and oversight of the study.

636

637


638 References


639	1.	Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the
640		Omicron (B.1.1.529) Variant. N Engl J Med 2022; 386 (16): 1532-46.
641	2.	Atmar RL, Lyke KE, Deming ME, et al. Homologous and Heterologous Covid-19
642		Booster Vaccinations. N Engl J Med 2022; 386 (11): 1046-57.
643	3.	Bekker LG, Garrett N, Goga A, et al. Effectiveness of the Ad26.COV2.S vaccine in
644		health-care workers in South Africa (the Sisonke study): results from a single-arm,
645		open-label, phase 3B, implementation study. Lancet 2022; 399 (10330): 1141-53.
646	4.	Hardt K, Vandebosch A, Sadoff J, et al. Efficacy, safety, and immunogenicity of a
647		booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results
648		of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Infect Dis
649		2022; 22 (12): 1703-15.
650	5.	Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose
651		Ad26.COV2.S Vaccine against Covid-19. N Engl J Med 2021; 384(23): 2187-201.
652	6.	Gray G, Collie S, Goga A, et al. Effectiveness of Ad26.COV2.S and BNT162b2
653		Vaccines against Omicron Variant in South Africa. N Engl J Med 2022; 386(23): 2243-
654		5.
655	7.	Bewley KR, Coombes NS, Gagnon L, et al. Quantification of SARS-CoV-2 neutralizing
656		antibody by wild-type plaque reduction neutralization, microneutralization and
657		pseudotyped virus neutralization assays. Nat Protoc 2021; 16(6): 3114-40.
658	8.	Fintzi J, Follmann D. Assessing vaccine durability in randomized trials following
659		placebo crossover. <i>Stat Med</i> 2021; 40 (27): 5983-6007.
660	9.	Florea A, Sy LS, Qian L, et al. Effectiveness of Messenger RNA-1273 Vaccine Booster
661		Against Coronavirus Disease 2019 in Immunocompetent Adults. Clin Infect Dis 2023;
662		76 (2): 252-62.

663	10.	Young-Xu Y, Zwain GM, Izurieta HS, et al. Effectiveness of mRNA COVID-19 vaccines
664		against Omicron and Delta variants in a matched test-negative case-control study
665		among US veterans. <i>BMJ Open</i> 2022; 12 (8): e063935.
666	11.	Nordstrom P, Ballin M, Nordstrom A. Effectiveness of heterologous ChAdOx1 nCoV-19
667		and mRNA prime-boost vaccination against symptomatic Covid-19 infection in
668		Sweden: A nationwide cohort study. Lancet Reg Health Eur 2021; 11: 100249.
669	12.	Natarajan K, Prasad N, Dascomb K, et al. Effectiveness of Homologous and
670		Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen
671		[Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency
672		Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION
673		Network, 10 States, December 2021-March 2022. MMWR Morb Mortal Wkly Rep
674		2022; 71 (13): 495-502.
675	13.	Pratama NR, Wafa IA, Budi DS, Putra M, Wardhana MP, Wungu CDK. mRNA Covid-
676		19 vaccines in pregnancy: A systematic review. <i>PLoS One</i> 2022; 17 (2): e0261350.
677	14.	Magnus MC, Ortqvist AK, Dahlqwist E, et al. Association of SARS-CoV-2 Vaccination
678		During Pregnancy With Pregnancy Outcomes. JAMA 2022; 327(15): 1469-77.
679	15.	Gonzalez VJ, Li L, Buarpung S, Prahl M, Robinson JF, Gaw SL. Minimal mRNA
680		uptake and inflammatory response to COVID-19 mRNA vaccine exposure in human
681		placental explants. <i>iScience</i> 2023; 26 (9): 107549.
682	16.	Africa SS. The Status of women in South Africa: Evidence from selected indicators,
683		2022.
684	17.	Delany-Moretlwe S, Lombard C, Baron D, et al. Tenofovir 1% vaginal gel for
685		prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3,
686		randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2018; 18(11):
687		1241-50.

688	18.	Gray GE, Allen M, Moodie Z, et al. Safety and efficacy of the HVTN 503/Phambili
689		study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised,
690		placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 2011; 11(7): 507-
691		15.
692	19.	Pattinson R FS, Gebhardt S, Soma-Pillay P, Niit R, Moodley J. The impact of COVID-
693		19 on use of maternal and reproductive health services and maternal and perinatal
694		mortality. South Afr Health Rev, 2022.
695	20.	Moodley Y, Tomita A, de Oliveira T, Tanser F. HIV viral load and pregnancy loss:
696		results from a population-based cohort study in rural KwaZulu-Natal, South Africa.
697		<i>AIDS</i> 2021; 35 (5): 829-33.
698	21.	Tukei VJ, Hoffman HJ, Greenberg L, et al. Adverse Pregnancy Outcomes Among HIV-
699		positive Women in the Era of Universal Antiretroviral Therapy Remain Elevated
700		Compared With HIV-negative Women. Pediatr Infect Dis J 2021; 40(9): 821-6.
701	22.	Blencowe H, Cousens S, Jassir FB, et al. National, regional, and worldwide estimates
702		of stillbirth rates in 2015, with trends from 2000: a systematic analysis. Lancet Glob
703		<i>Health</i> 2016; 4 (2): e98-e108.
704	23.	Tan CS, Collier AY, Yu J, et al. Durability of Heterologous and Homologous COVID-19
705		Vaccine Boosts. JAMA Netw Open 2022; 5(8): e2226335.
706	24.	Khoo NKH, Lim JME, Gill US, et al. Differential immunogenicity of homologous versus
707		heterologous boost in Ad26.COV2.S vaccine recipients. Med 2022; 3(2): 104-18 e4.
708	25.	Barouch DH, Stephenson KE, Sadoff J, et al. Durable Humoral and Cellular Immune
709		Responses 8 Months after Ad26.COV2.S Vaccination. N Engl J Med 2021; 385(10):
710		951-3.
711	26.	Sablerolles RSG, Rietdijk WJR, Goorhuis A, et al. Durability of Immune Responses
712		After Boosting in Ad26.COV2.S-Primed Healthcare Workers. Clin Infect Dis 2023;
713		76 (3): e533-e6.

- 27. Barros-Martins J, Hammerschmidt SI, Cossmann A, et al. Immune responses against
- 715 SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-
- 716 19/BNT162b2 vaccination. *Nat Med* 2021; **27**(9): 1525-9.
- 28. Garrett N, Tapley A, Andriesen J, et al. High Asymptomatic Carriage With the Omicron
- 718 Variant in South Africa. *Clin Infect Dis* 2022; **75**(1): e289-e92.
- 29. Madhi SA, Kwatra G, Myers JE, et al. Population Immunity and Covid-19 Severity with
- 720 Omicron Variant in South Africa. *N Engl J Med* 2022; **386**(14): 1314-26.








423


Baseline W4 W24 Median: 562 554 726 753 360 and and and at


....











Median FC